- 20 Jul 2018, 14:24
#2781
a) We initiated a directive which strictly prohibit use of Ionotrops and Vasopressors on patients in ward (being high risk drugs),
Clarithromycin 500mg requires minimum of 250mL NS to be diluted, else solution is turbid and causes pain / inflammation (phlebitis),
Albumin 100mL to be administered over four hours only for all patients with low EF,
b) Recently an infant diagnosed with invasive ESBL Klebsiella which was PAN XDR resistant to all available panel of antibiotics except Minocycline.
We were out of choice but took a decision to use Minocycline (which has no data on its used in Infants or neonates).
Patient was weaned off ventilator and discharge with fully recovered bilateral pneumonia.
c) Use of Intrventricular Colistin in Acinetobacter baummanii ventriculitis
and so on.....it is a regular process
swathi wrote: ↑20 Jul 2018, 13:43 Dear Dr. Govinda, are you involved in any clinical decision making? If so , can you specify any one of such decision which made you feel proud as a clinical pharmacist.Yes I am involved in such decisions. Most of them relate to Drug dosing, Frequency, calculation and solution compatibility.
a) We initiated a directive which strictly prohibit use of Ionotrops and Vasopressors on patients in ward (being high risk drugs),
Clarithromycin 500mg requires minimum of 250mL NS to be diluted, else solution is turbid and causes pain / inflammation (phlebitis),
Albumin 100mL to be administered over four hours only for all patients with low EF,
b) Recently an infant diagnosed with invasive ESBL Klebsiella which was PAN XDR resistant to all available panel of antibiotics except Minocycline.
We were out of choice but took a decision to use Minocycline (which has no data on its used in Infants or neonates).
Patient was weaned off ventilator and discharge with fully recovered bilateral pneumonia.
c) Use of Intrventricular Colistin in Acinetobacter baummanii ventriculitis
and so on.....it is a regular process